Brian Topp

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

12h-index1.2kcitations31works3.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(13), Pancreatic function and diabetes(7), Diabetes and associated disorders(5), Metabolism, Diabetes, and Cancer(5), Computational Drug Discovery Methods(4)

Publications31 total

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma
Blood Advances·2025Open Access
Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer
2025
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Journal for ImmunoTherapy of Cancer·2024· 12 citedOpen Access
A bootstrapping method to optimize go/no‐go decisions from single‐arm, signal‐finding studies in oncology
CPT Pharmacometrics & Systems Pharmacology·2024· 3 citedOpen Access
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression
Cancer Cell·2023· 39 citedOpen Access
P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA
HemaSphere·2023Open Access
Incorporating lesion-to-lesion heterogeneity into early oncology decision making
UNC Libraries·2023Open Access
Incorporating lesion-to-lesion heterogeneity into early oncology decision making
Frontiers in Immunology·2023· 8 citedOpen Access
FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB
Hematological Oncology·2023· 1 citedOpen Access
RECISTv1.1 progression in oncology: Shades of gray
Cancer Cell·2023· 13 citedOpen Access
Abstract 4384: Does progressive disease justify pembrolizumab discontinuation: a simulation analysis
Cancer Research·2023
Abstract 4375: A bootstrapping method to optimize go/no-go decisions from single-arm, signal-finding studies in oncology
Cancer Research·2023
Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors
Cancers·2021· 4 citedOpen Access
Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab
Annals of Oncology·2021· 26 citedOpen Access
Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response
CPT Pharmacometrics & Systems Pharmacology·2021· 20 citedOpen Access
Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1
British Journal of Cancer·2021· 6 citedOpen Access
Abstract PO-131: Inter-tumoral heterogeneity of progressive disease in melanoma patients treated with pembrolizumab
Cancer Research·2020· 1 cited
Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities
CPT Pharmacometrics & Systems Pharmacology·2019· 85 citedOpen Access
Industrialization of Quantitative Systems Pharmacology
CPT Pharmacometrics & Systems Pharmacology·2019· 3 citedOpen Access
Fix the grid: how Canada can integrate its electricity systems for a clean, prosperous future
2019
page 1 of 2Next →

Frequent Co-authors

Diane T. Finegood(6), Alexandra Snyder(5), Rukmini Kumar(4), Dinesh de Alwis(4), Kapil Mayawala(3), Philippe Armand(3), Pier Luigi Zinzani(3), John M. Timmerman(3), Nathalie A. Johnson(3), David Lavie(3), Pallavi Pillai(3), Alex F. Herrera(3), Kannan Thiagarajan(3), M. Dawn McArthur(2), Mary E. Spilker(2), Loveleena Bansal(2), Kha Le(2), Mark Penney(2), Edgar Schuck(2), Alice Tsai(2)